Next Day Disclosure Return
Filed with HKEX · Stock code 2269 · · 6 pages · English
Wuxi Biologics (Cayman) Inc. on 6ix
Earlier from Wuxi Biologics (Cayman)
- WuXi Biologics Reports Strong Profitable Growth in H1 2026
- WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
- WuXi Biologics Cayman Announces Divestment of Controlling Stake in Bestchrom
- WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
- WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
Later from Wuxi Biologics (Cayman)
- Interim Report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence
Follow Wuxi Biologics (Cayman) into a list and get an email when it puts out news.
Follow Wuxi Biologics (Cayman)